Comparison of Prognosis and Health-Related Quality of Life Between Robot-Assisted Radical Prostatectomy Versus High-Dose-Rate Brachytherapy Combined With External Beam Radiation Therapy and Hormone Therapy for High-Risk Prostate Cancer.
{"title":"Comparison of Prognosis and Health-Related Quality of Life Between Robot-Assisted Radical Prostatectomy Versus High-Dose-Rate Brachytherapy Combined With External Beam Radiation Therapy and Hormone Therapy for High-Risk Prostate Cancer.","authors":"Yuya Iwahashi, Takahito Wakamiya, Hiroki Kawabata, Ryusuke Deguchi, Satoshi Muraoka, Takaya Inagaki, Yasutaka Noda, Shimpei Yamashita, Yasuo Kohjimoto, Tetsuo Sonomura, Isao Hara","doi":"10.1002/pros.24831","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We compare the oncological outcomes and health-related quality of life (HRQOL) in men with high-risk prostate cancer after robot-assisted radical prostatectomy (RARP) versus that after high-dose-rate brachytherapy + external beam radiotherapy + hormone therapy (hereafter: \"HDR+\").</p><p><strong>Methods: </strong>We included 233 men who underwent RARP and 179 men who underwent HDR+ for high-risk prostate cancer at our hospital. We investigated the following oncologic outcomes: time to biochemical recurrence, time to development of castration-resistant prostate cancer (CRPC), cancer-specific survival, and overall survival. HRQOL was assessed using SF-8 and Expanded Prostate Cancer Index Composite (EPIC) at baseline and at 3, 6, 12, and 24 months after treatment. Propensity score matching was performed to adjust the background of the two treatment groups.</p><p><strong>Results: </strong>The HDR+ group had a significantly lower rate of biochemical recurrence than the RARP group (p ≤ 0.01). There were no significant differences between the two groups in the time to CRPC, in cancer-specific survival, or in overall survival. The two groups had similar HRQOL, according to SF-8. The urinary domain of EPIC was significantly worse in the RARP group at 3 and 6 months postoperatively than in the HDR+ group (p ≤ 0.01). Urinary function and urinary incontinence were significantly worse in the RARP group than in the HDR+ group at all time points postoperatively (p ≤ 0.01), while urinary irritation/obstruction was significantly worse in the HDR+ group at 12 months than in the RARP group (p ≤ 0.01). Bowel function was similar between the two groups.</p><p><strong>Conclusions: </strong>Both RARP and HDR+ were considered to be effective treatments for patients with high-risk prostate cancer in terms of oncological outcomes. Our RARP group had more postoperative urinary incontinence than our HDR+ group, while the HDR+ group had more frequent urination as a symptom of late genitourinary toxicity than the RARP group.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"327-336"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pros.24831","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: We compare the oncological outcomes and health-related quality of life (HRQOL) in men with high-risk prostate cancer after robot-assisted radical prostatectomy (RARP) versus that after high-dose-rate brachytherapy + external beam radiotherapy + hormone therapy (hereafter: "HDR+").
Methods: We included 233 men who underwent RARP and 179 men who underwent HDR+ for high-risk prostate cancer at our hospital. We investigated the following oncologic outcomes: time to biochemical recurrence, time to development of castration-resistant prostate cancer (CRPC), cancer-specific survival, and overall survival. HRQOL was assessed using SF-8 and Expanded Prostate Cancer Index Composite (EPIC) at baseline and at 3, 6, 12, and 24 months after treatment. Propensity score matching was performed to adjust the background of the two treatment groups.
Results: The HDR+ group had a significantly lower rate of biochemical recurrence than the RARP group (p ≤ 0.01). There were no significant differences between the two groups in the time to CRPC, in cancer-specific survival, or in overall survival. The two groups had similar HRQOL, according to SF-8. The urinary domain of EPIC was significantly worse in the RARP group at 3 and 6 months postoperatively than in the HDR+ group (p ≤ 0.01). Urinary function and urinary incontinence were significantly worse in the RARP group than in the HDR+ group at all time points postoperatively (p ≤ 0.01), while urinary irritation/obstruction was significantly worse in the HDR+ group at 12 months than in the RARP group (p ≤ 0.01). Bowel function was similar between the two groups.
Conclusions: Both RARP and HDR+ were considered to be effective treatments for patients with high-risk prostate cancer in terms of oncological outcomes. Our RARP group had more postoperative urinary incontinence than our HDR+ group, while the HDR+ group had more frequent urination as a symptom of late genitourinary toxicity than the RARP group.
期刊介绍：
The Prostate is a peer-reviewed journal dedicated to original studies of this organ and the male accessory glands. It serves as an international medium for these studies, presenting comprehensive coverage of clinical, anatomic, embryologic, physiologic, endocrinologic, and biochemical studies.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
